<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="deo270030" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">DEN Open</journal-id><journal-id journal-id-type="iso-abbrev">DEN Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2692-4609</journal-id><journal-id journal-id-type="publisher-id">DEO2</journal-id><journal-title-group><journal-title>DEN Open</journal-title></journal-title-group><issn pub-type="epub">2692-4609</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39449767</article-id><article-id pub-id-type="pmc">PMC11499709</article-id>
<article-id pub-id-type="doi">10.1002/deo2.70030</article-id><article-id pub-id-type="publisher-id">DEO270030</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Clinical usefulness of hybrid endoscopic submucosal dissection for T1b colorectal carcinomas &#x02264;20 mm to ensure adequate vertical margins</article-title><alt-title alt-title-type="left-running-head">TAKEHARA <sc>et al</sc>.</alt-title></title-group><contrib-group><contrib id="deo270030-cr-0001" contrib-type="author"><name><surname>Takehara</surname><given-names>Yudai</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0002" contrib-type="author" corresp="yes"><name><surname>Yamashita</surname><given-names>Ken</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0000-0350-8553</contrib-id><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref><address><email>kenyama5@hiroshima-u.ac.jp</email></address></contrib><contrib id="deo270030-cr-0003" contrib-type="author"><name><surname>Morimoto</surname><given-names>Shin</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0004" contrib-type="author"><name><surname>Tanino</surname><given-names>Fumiaki</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0005" contrib-type="author"><name><surname>Yamamoto</surname><given-names>Noriko</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0006" contrib-type="author"><name><surname>Kamigaichi</surname><given-names>Yuki</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0007" contrib-type="author"><name><surname>Tanaka</surname><given-names>Hidenori</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-3646-5796</contrib-id><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0008" contrib-type="author"><name><surname>Takigawa</surname><given-names>Hidehiko</given-names></name><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0009" contrib-type="author"><name><surname>Urabe</surname><given-names>Yuji</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-9851-8564</contrib-id><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib id="deo270030-cr-0010" contrib-type="author"><name><surname>Kuwai</surname><given-names>Toshio</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9956-1358</contrib-id><xref rid="deo270030-aff-0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib id="deo270030-cr-0011" contrib-type="author"><name><surname>Arihiro</surname><given-names>Koji</given-names></name><xref rid="deo270030-aff-0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib id="deo270030-cr-0012" contrib-type="author"><name><surname>Oka</surname><given-names>Shiro</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1652-0743</contrib-id><xref rid="deo270030-aff-0001" ref-type="aff">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="deo270030-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Gastroenterology</named-content>
<institution>Hiroshima University Hospital</institution>
<city>Hiroshima</city>
<country country="JP">Japan</country>
</aff><aff id="deo270030-aff-0002">
<label>
<sup>2</sup>
</label>
<institution>Gastrointestinal Endoscopy and Medicine</institution>
<institution>Hiroshima University Hospital</institution>
<city>Hiroshima</city>
<country country="JP">Japan</country>
</aff><aff id="deo270030-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Anatomical Pathology</named-content>
<institution>Hiroshima University Hospital</institution>
<city>Hiroshima</city>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold>
<break/>Ken Yamashita, Department of Gastroenterology, Hiroshima University Hospital, 1&#x02010;2&#x02010;3 Kasumi, Minami&#x02010;ku, Hiroshima 734&#x02013;8551, Japan.<break/> Email: <email>kenyama5@hiroshima-u.ac.jp</email>
<break/>
</corresp></author-notes><pub-date pub-type="epub"><day>24</day><month>10</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><volume>5</volume><issue seq="64">1</issue><issue-id pub-id-type="doi">10.1002/deo2.v5.1</issue-id><elocation-id>e70030</elocation-id><history>
<date date-type="rev-recd"><day>03</day><month>10</month><year>2024</year></date>
<date date-type="received"><day>14</day><month>8</month><year>2024</year></date>
<date date-type="accepted"><day>08</day><month>10</month><year>2024</year></date>
</history><permissions><!--&#x000a9; 2025 John Wiley & Sons Ltd.--><copyright-statement content-type="article-copyright">&#x000a9; 2024 The Author(s). <italic toggle="yes">DEN Open</italic> published by John Wiley &#x00026; Sons Australia, Ltd on behalf of Japan Gastroenterological Endoscopy Society.</copyright-statement><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:DEO2-5-e70030.pdf"/><abstract><title>Abstract</title><sec id="deo270030-sec-0010"><title>Objective</title><p>To evaluate endoscopic resection strategies for cT1b colorectal carcinomas (CRCs) &#x02264;20 mm to determine strategies that enable adequate vertical margins (VMs).</p></sec><sec id="deo270030-sec-0020"><title>Methods</title><p>We enrolled 128 consecutive patients with cT1b colorectal carcinomas &#x02264;20 mm resected by endoscopic mucosal resection or hybrid endoscopic submucosal dissection (ESD). Tumor lifting conditions after submucosal injection were classified into type A (lifting, soft dome&#x02010;like), type B (lifting, hard trapezoid&#x02010;like), and non&#x02010;lifting (positive non&#x02010;lifting sign). Predictors of positive VMs (VM 1) and adequate VMs were identified.</p></sec><sec id="deo270030-sec-0030"><title>Results</title><p>All non&#x02010;lifting tumors were resected by hybrid ESD and VMs were &#x02265;500 &#x000b5;m. Vertical margin 1 tumors were only found in the endoscopic mucosal resection&#x000a0;group, in which, the proportion of type B tumors with VM 1 was significantly higher than that of tumors with negative VMs (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01). Type A tumors showed no significant between&#x02010;group differences. Among type B tumors, the proportion of VMs &#x02265;500 &#x000b5;m was significantly higher (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and the VM distance was significantly longer (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) in the hybrid ESD group than in the endoscopic mucosal resection group.</p></sec><sec id="deo270030-sec-0040"><title>Conclusions</title><p>Hybrid ESD can be selected for type B tumors to ensure adequate VMs.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="deo270030-kwd-0001">colorectal carcinoma</kwd><kwd id="deo270030-kwd-0002">endoscopic mucosal resection</kwd><kwd id="deo270030-kwd-0003">endoscopic submucosal dissection</kwd><kwd id="deo270030-kwd-0004">recurrence</kwd><kwd id="deo270030-kwd-0005">tumor</kwd></kwd-group><funding-group><award-group id="funding-0001"><funding-source>None</funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="6"/><page-count count="10"/><word-count count="5334"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>April 2025</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.4 mode:remove_FC converted:27.02.2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="deo270030-sec-0050"><title>INTRODUCTION</title><p>The number of treated submucosal invasive (T1) colorectal carcinomas (CRCs) and endoscopic resections (ERs) for T1 CRCs have been increasing annually.<xref rid="deo270030-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> The Japanese Society for Cancer of the Colon and Rectum (JSCCR) 2022 guidelines<xref rid="deo270030-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> state that intramucosal and superficial submucosal invasive (T1a) CRCs (invasion depth &#x0003c;1000 &#x000b5;m) are indications for en bloc ER; moreover, intestinal resection with lymph node dissection is indicated for deep submucosal invasion (T1b) CRCs (&#x02265;1000 &#x000b5;m). However, pathological conditions of T1b CRCs with an extremely low lymph node metastasis risk are identified<xref rid="deo270030-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="deo270030-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="deo270030-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="deo270030-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>; therefore, indications for ER are being considered. A negative vertical margin (VM) is an absolute requirement for curative ER according to the JSCCR, National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines.<xref rid="deo270030-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270030-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo270030-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> The current Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma states that desirable resection by ER (VM distance) is &#x02265;500 &#x000b5;m from the deepest invasion front of the carcinoma to the marginal termination resected.<xref rid="deo270030-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> Complete en bloc resection with VM distance &#x02265;500 &#x000b5;m during ER for T1 CRC reduces the metastatic recurrence risk after additional surgery.<xref rid="deo270030-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> An adequate VM distance is required; however, ER strategies for T1 CRC that ensure adequate VMs remain unclear.</p><p>Endoscopic mucosal resection (EMR), the primary standard method for colorectal tumors,<xref rid="deo270030-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref>, <xref rid="deo270030-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref>, <xref rid="deo270030-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref> is limited to lesions &#x02264;20 mm because of the snare diameter. When en bloc resection is possible, EMR is a standard method for non&#x02010;pedunculated tumors &#x02264;20 mm suspected to be cancer.<xref rid="deo270030-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="deo270030-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref> Submucosal injection is important for EMR, and EMR is difficult when lesions display positive non&#x02010;lifting signs,<xref rid="deo270030-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270030-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> which are commonly seen in tumors with fibrosis or cT1b CRCs. In contrast, endoscopic submucosal dissection (ESD) enables complete en bloc resection irrespective of lesion size<xref rid="deo270030-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270030-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="deo270030-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> and can be performed for lesions &#x02264;20 mm with submucosal fibrosis or cT1b CRCs that are difficult to resect using en bloc EMR. ESD is technically more difficult than EMR requires more time and poses a higher perforation risk.<xref rid="deo270030-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="deo270030-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref> Recently, hybrid ESD, a modified ESD technique, has gained popularity.<xref rid="deo270030-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="deo270030-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="deo270030-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="deo270030-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="deo270030-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref> It simplifies submucosal dissection, resulting in decreased procedure times and complications. We retrospectively evaluated ER strategies for cT1b CRCs &#x02264;20 mm resected by EMR or hybrid ESD based on the findings following submucosal injection to determine strategies that ensure adequate VMs.</p></sec><sec id="deo270030-sec-0060"><title>METHODS</title><sec id="deo270030-sec-0070"><title>Patients</title><p>This retrospective, single&#x02010;center study included 128 consecutive patients with 128 cT1b CRCs &#x02264;20 mm resected by EMR or hybrid ESD at Hiroshima University Hospital between August 2009 and December 2022. For cT1b CRCs &#x02264;20 mm, 108 patients underwent primary surgery and 50 underwent conventional ESD during the same period; these patients were excluded. Four pedunculated tumors were excluded. We focused on EMR and performed comparisons in terms of snaring. Tumors (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;124) resected by EMR (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;93) or hybrid ESD (<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;31) were included. After explaining the procedure to the patients, ER was performed in older patients or patients with serious complications, those who refused surgical resection and preferred ESD, and those with Rb lesions (from peritoneal reflection to the upper border of the puborectal muscle attachment) that could diminish their quality of life postoperatively because of possible colostomy and defecation, urination, and sexual dysfunctions.</p><p>Tumor lifting conditions after submucosal injection were classified before ER into type A (complete lifting with a soft, dome&#x02010;like form), type B (complete lifting with a hard, trapezoid&#x02010;like form), and non&#x02010;lifting (positive non&#x02010;lifting sign<xref rid="deo270030-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270030-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> that indicated slight lifting with better lifting of the surrounding mucosa or no lifting; Figure&#x000a0;<xref rid="deo270030-fig-0001" ref-type="fig">1</xref>). Two expert endoscopists retrospectively assessed the lifting conditions by reviewing images after submucosal injection and determined the lifting types before reviewing the ER procedure results. Interobserver variability for the classification was &#x0003c;5%.</p><fig position="float" fig-type="FIGURE" id="deo270030-fig-0001"><label>FIGURE 1</label><caption><p>Classifications of tumor lifting conditions after submucosal injection: type A, complete lifting and soft dome&#x02010;like form; type B, complete lifting and hard trapezoid&#x02010;like form; and non&#x02010;lifting, slight lifting with better lifting of the surrounding mucosa or no lifting.</p></caption><graphic xlink:href="DEO2-5-e70030-g001" position="anchor" id="jats-graphic-1"/></fig></sec><sec id="deo270030-sec-0080"><title>EMR and hybrid ESD procedures</title><p>Five highly experienced endoscopists experienced in &#x0003e;30 colorectal ESD procedures performed ERs and selected the methods for cT1b CRCs based on the clinicopathological lesion characteristics.</p><p>During EMR, a 10% glycerin solution containing indigo carmine (indigo carmine/solution: 0.2/20 mL) was injected into the tumor's submucosal layer. The elevated lesion was excised by constriction with a 10&#x02010;, 15&#x02010;, or 20&#x02010;mm snare (SnareMaster; Olympus or Captivator; Boston Scientific).</p><p>During hybrid ESD, a local solution with the same composition as that used for EMR was injected into the tumor's submucosal layer. DualKnife (Olympus) or 15&#x02010;mm SOUTEN (Kaneka Medics) was used as the ESD knife. A 20&#x02010;mm SnareMaster snare (Olympus) or 15&#x02010;mm SOUTEN (Kaneka Medics) was used for snaring. The SM dissection extent before snare resection was determined by each endoscopist depending on the lesion and situation. A transparent tip hood made submucosal layer entry easier and ensured good visibility.<xref rid="deo270030-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref> All lesions were diagnosed as cT1b CRCs; we dissected the submucosa just above the muscle layer and below the tumor.</p><p>To form an ideal tumor lifting condition that facilitates resection, the lesion was positioned towards the 6 o'clock direction on the screen, and the solution was injected from the lesion's anal side using a down&#x02010;angle to ensure adequate injection of the solution directly beneath it. The submucosal injection was basically performed as a single injection to prevent solution spread. The electrosurgical unit was VIO300D (ERBE). During EMR, the ENDO CUT Q mode (effect2, time2, duration3) was used for snaring. During hybrid ESD, the ENDO CUT I (effect3, time2, duration2), swift coagulation (effect3, 30 W), and ENDO CUT Q (effect2, time2, duration3) modes were used for mucosal incision, SM dissection, and snaring, respectively.</p></sec><sec id="deo270030-sec-0090"><title>cT1b CRC definition</title><p>We performed normal endoscopic observation, magnified endoscopy of the pit pattern using magnifying chromoendoscopy, endoscopic ultrasonography (EUS), and barium enema evaluations for cT1b CRC diagnosis. Expanded appearance, deeply depressed surfaces, folds converging toward the tumor, type V<sub>I</sub>&#x02010;severe<xref rid="deo270030-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref> or V<sub>N</sub> pit pattern on chromoendoscopy, submucosal layer invasion on EUS, and a smooth surface, fold convergency, or eccentric rigidity in barium enema led to suspicion of cT1b CRC.<xref rid="deo270030-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref> After considering all factors, cT1b CRC was diagnosed.</p></sec><sec id="deo270030-sec-0100"><title>Histopathological diagnosis</title><p>Endoscopically resected specimens were fixed with 10% formalin and cut into 2&#x02010;mm&#x02010;thick sections. Pathological characteristics (tumor diameter, histologic type, submucosal invasion depth, lymphovascular invasion, budding grade, and resection margin) were evaluated according to the JSCCR 2022 guidelines.<xref rid="deo270030-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> En bloc resection was defined as single&#x02010;piece resection. VM1 was defined as the presence of tumor cells at the submucosal VM of resected specimens. The distance from the tumor invasive front to the VM of resected specimens (VM distance) was measured using a digital measurement system (DP2&#x02010;SAL; Olympus). VM distance in high&#x02010;grade dysplasia was defined as the distance from the muscularis mucosae to the VM of resected specimens. VM distance of VM1 tumors was defined as 0 &#x000b5;m. According to the treatment strategy after ER for pT1 CRCs indicated by the JSCCR 2022 guidelines,<xref rid="deo270030-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref> we strongly recommended intestinal resection with lymph node dissection for VM1 lesions. For VM&#x02010;negative pT1b CRCs, resection with intestinal lymph node dissection was considered; therefore, we consulted with surgeons and selected a treatment policy based on histopathological risk factors (main histology, vascular invasion, and budding grade), patients&#x02019; wishes, and background factors. One expert gastrointestinal pathologist, blinded to the ER method, diagnosed and measured vertical tumor margin distances.</p></sec><sec id="deo270030-sec-0110"><title>Evaluation</title><p>EMR and hybrid ESD groups were analyzed to identify predictors of VM1 and adequate VM distance, including location, tumor size, gross type, tumor lifting conditions, histologic findings (main histology, histology at the deepest invasive front, submucosal invasion depth, vascular invasion, and budding grade), rebleeding, and perforation.</p></sec><sec id="deo270030-sec-0120"><title>Statistical analysis</title><p>All variables are expressed as mean with standard deviation, median with range, or number with percentage. Distributions of continuous variables were compared using the Student's <italic toggle="yes">t</italic>&#x02010;test or Mann&#x02013;Whitney <italic toggle="yes">U</italic> test. Associations between categorical variables and outcomes were examined using Pearson's chi&#x02010;square test and Fisher's exact test. Statistical analyses were performed using JMP software version 17.0.0 (SAS Institute Inc.), with statistical significance set at <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="deo270030-sec-0130"><title>RESULTS</title><sec id="deo270030-sec-0140"><title>Comparison of overall outcomes</title><p>Table&#x000a0;<xref rid="deo270030-tbl-0001" ref-type="table">1</xref> shows the clinicopathological characteristics and outcomes of tumors in the EMR (93 tumors) and hybrid ESD (31 tumors) groups. The mean age and sex ratio (male:female) in the EMR and hybrid ESD groups were 70.0&#x000a0;&#x000b1;&#x000a0;9.0 years and 63:30 and 69.8&#x000a0;&#x000b1;&#x000a0;11.3 years and 18:13, respectively. The proportions of rectal tumors (32.3% [10/31] vs. 12.9% [12/93], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05), type B tumor lifting condition (32.3% [10/31] vs. 24.7% [23/93], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), budding grade 2/3 (45.2% [14/31] vs. 23.7% [22/93], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05), and VM &#x02265;500 &#x000b5;m (90.3% [28/31] vs. 62.4% [58/93], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) were significantly higher in the hybrid ESD group than in the EMR group. The proportion of VM1 tumors was significantly higher in the EMR group (12.9% [12/93] vs. 0% [0/31], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Other clinicopathological characteristics and outcomes showed no significant between&#x02010;group differences. All three non&#x02010;lifting tumors were resected using hybrid ESD. For two of them, EMR was converted to hybrid ESD on the same day because of tumor lifting conditions. For three tumors, a certain distance between the deepest invasive tumor front and muscle layer was confirmed preoperatively using EUS; therefore, en bloc resection using hybrid ESD was considered possible. The VM distance of these non&#x02010;lifting tumors was &#x02265;500 &#x000b5;m. No tumor required conversion from ESD to EMR. Sixty&#x02010;five patients with 65 tumors underwent additional surgery after ER, with no local tumor remnants. The mean time for hybrid ESD was 29.9&#x000a0;&#x000b1;&#x000a0;14.6 min, and clip closure to the post&#x02010;ER ulcer was generally not performed after the procedure. Exceptionally, clipping only at the perforation or damaged site was performed in cases of perforation or severe damage to the muscle layer at the post&#x02010;ER ulcer.</p><table-wrap position="float" id="deo270030-tbl-0001" content-type="TABLE"><label>TABLE 1</label><caption><p>Clinicopathological characteristics and outcomes of tumors in the endoscopic mucosal resection (EMR) and hybrid endoscopic submucosal dissection (ESD) groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">EMR group</th><th align="left" rowspan="1" colspan="1">Hybrid ESD group</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;93</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;31</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">70.0&#x000a0;&#x000b1;&#x000a0;9.0</td><td align="left" rowspan="1" colspan="1">69.8&#x000a0;&#x000b1;&#x000a0;11.3</td><td align="char" rowspan="1" colspan="1">0.9184</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">63 (67.7)</td><td align="char" rowspan="1" colspan="1">18 (58.1)</td><td align="char" rowspan="1" colspan="1">0.3852</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">30 (32.3)</td><td align="char" rowspan="1" colspan="1">13 (41.9)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Colon</td><td align="char" rowspan="1" colspan="1">81 (87.1)</td><td align="char" rowspan="1" colspan="1">21 (67.7)</td><td align="char" rowspan="1" colspan="1">0.0270</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">12 (12.9)</td><td align="char" rowspan="1" colspan="1">10 (32.3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor size, mm, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">11.8&#x000a0;&#x000b1;&#x000a0;5.0</td><td align="left" rowspan="1" colspan="1">13.8&#x000a0;&#x000b1;&#x000a0;4.3</td><td align="char" rowspan="1" colspan="1">0.0446</td></tr><tr><td align="left" rowspan="1" colspan="1">Gross type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Protruded</td><td align="char" rowspan="1" colspan="1">75 (80.7)</td><td align="char" rowspan="1" colspan="1">17 (54.8)</td><td align="char" rowspan="1" colspan="1">0.0082</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Superficial</td><td align="char" rowspan="1" colspan="1">18 (19.3)</td><td align="char" rowspan="1" colspan="1">14 (45.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor lifting condition, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Type A</td><td align="char" rowspan="1" colspan="1">70 (75.3)</td><td align="char" rowspan="1" colspan="1">18 (58.1)</td><td align="char" rowspan="1" colspan="1">0.0053</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Type B</td><td align="char" rowspan="1" colspan="1">23 (24.7)</td><td align="char" rowspan="1" colspan="1">10 (32.3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Non&#x02010;lifting</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">3 (9.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Main histology, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">91 (97.9)</td><td align="char" rowspan="1" colspan="1">30 (96.7)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">2 (2.1)</td><td align="char" rowspan="1" colspan="1">1 (3.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histology at the deepest invasive front, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">82 (88.2)</td><td align="char" rowspan="1" colspan="1">28 (90.3)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">11 (11.8)</td><td align="char" rowspan="1" colspan="1">3 (9.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic findings, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HGD</td><td align="char" rowspan="1" colspan="1">10 (10.8)</td><td align="char" rowspan="1" colspan="1">2 (6.5)</td><td align="char" rowspan="1" colspan="1">0.3067</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1a carcinoma</td><td align="char" rowspan="1" colspan="1">5 (5.4)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1b carcinoma</td><td align="char" rowspan="1" colspan="1">78 (83.8)</td><td align="char" rowspan="1" colspan="1">29 (93.5)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SM depth, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">2000 [1200&#x02013;3500]</td><td align="left" rowspan="1" colspan="1">2000 [1300&#x02013;3000]</td><td align="char" rowspan="1" colspan="1">0.9838</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion positive, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">27 (29.0)</td><td align="char" rowspan="1" colspan="1">14 (45.2)</td><td align="char" rowspan="1" colspan="1">0.1236</td></tr><tr><td align="left" rowspan="1" colspan="1">Budding grade 2/3, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">22 (23.7)</td><td align="char" rowspan="1" colspan="1">14 (45.2)</td><td align="char" rowspan="1" colspan="1">0.0381</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">91 (97.9)</td><td align="char" rowspan="1" colspan="1">31 (100)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">VM distance, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">750 [325&#x02013;1600]</td><td align="left" rowspan="1" colspan="1">700 [500&#x02013;1800]</td><td align="char" rowspan="1" colspan="1">0.3660</td></tr><tr><td align="left" rowspan="1" colspan="1">VM &#x02265;500&#x000b5;m, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">58 (62.4)</td><td align="char" rowspan="1" colspan="1">28 (90.3)</td><td align="char" rowspan="1" colspan="1">0.0032</td></tr><tr><td align="left" rowspan="1" colspan="1">VM1, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">12 (12.9)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0.0364</td></tr><tr><td align="left" rowspan="1" colspan="1">Rebleeding, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">2 (2.2)</td><td align="char" rowspan="1" colspan="1">1 (3.2)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">Perforation, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl1-note-0001"><p>Abbreviations: EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high&#x02010;grade dysplasia; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; SD, standard deviation; sig, signet&#x02010;ring cell carcinoma; SM, submucosal; tub, tubular adenocarcinoma; VM, vertical margin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270030-sec-0150"><title>Risk factors for VM1 and VM &#x0003c;500 &#x000b5;m</title><p>VM1 tumors were only seen in the EMR group; therefore, we compared the clinical characteristics of VM1 and VM&#x02010;negative tumors in the EMR group to identify clinical factors associated with VM1 (Table&#x000a0;<xref rid="deo270030-tbl-0002" ref-type="table">2</xref>). The proportion of type B lifting condition was significantly higher for VM1 tumors than for VM&#x02010;negative tumors (100% [12/12] vs. 13.6% [11/81], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01). No significant between&#x02010;group differences were observed in location, tumor size, or gross type of VM1 and VM&#x02010;negative tumors. Table&#x000a0;<xref rid="deo270030-tbl-0003" ref-type="table">3</xref> presents univariate and multivariate logistic regression analyses of tumor features associated with VM &#x0003c;500 &#x000b5;m (colon location, tumor size &#x02264;15 mm, superficial type, type B lifting condition, and pathological T1b); the results showed that the type B lifting condition was significantly associated with VM &#x0003c;500 &#x000b5;m.</p><table-wrap position="float" id="deo270030-tbl-0002" content-type="TABLE"><label>TABLE 2</label><caption><p>Clinical characteristics of tumors in the vertical margin 1 (VM1) and VM&#x02010;negative endoscopic mucosal resection (EMR) groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">VM1</th><th align="left" rowspan="1" colspan="1">VM&#x02010;negative</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;12</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;81</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">69.4&#x000a0;&#x000b1;&#x000a0;13.4</td><td align="left" rowspan="1" colspan="1">70.1&#x000a0;&#x000b1;&#x000a0;8.2</td><td align="char" rowspan="1" colspan="1">0.4717</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">7 (58.3)</td><td align="char" rowspan="1" colspan="1">56 (69.1)</td><td align="char" rowspan="1" colspan="1">0.5146</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">5 (41.7)</td><td align="char" rowspan="1" colspan="1">25 (30.9)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Colon</td><td align="char" rowspan="1" colspan="1">10 (83.3)</td><td align="char" rowspan="1" colspan="1">71 (87.7)</td><td align="char" rowspan="1" colspan="1">0.6508</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">2 (16.7)</td><td align="char" rowspan="1" colspan="1">10 (12.3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Tumor size, mm, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">11.3&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="left" rowspan="1" colspan="1">11.9&#x000a0;&#x000b1;&#x000a0;5.1</td><td align="char" rowspan="1" colspan="1">0.6894</td></tr><tr><td align="left" rowspan="1" colspan="1">Gross type</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Protruded</td><td align="char" rowspan="1" colspan="1">10 (83.3)</td><td align="char" rowspan="1" colspan="1">65 (80.3)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Superficial</td><td align="char" rowspan="1" colspan="1">2 (16.7)</td><td align="char" rowspan="1" colspan="1">16 (19.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor lifting condition, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Type A</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">70 (86.4)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Type B</td><td align="char" rowspan="1" colspan="1">12 (100)</td><td align="char" rowspan="1" colspan="1">11 (13.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic findings, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HGD</td><td align="char" rowspan="1" colspan="1">1 (8.3)</td><td align="char" rowspan="1" colspan="1">9 (11.1)</td><td align="char" rowspan="1" colspan="1">0.6327</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1a carcinoma</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">5 (6.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1b carcinoma</td><td align="char" rowspan="1" colspan="1">11 (91.7)</td><td align="char" rowspan="1" colspan="1">67 (82.7)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SM depth, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">2800 [2275&#x02013;3000]</td><td align="left" rowspan="1" colspan="1">2000 [1200&#x02013;3600]</td><td align="char" rowspan="1" colspan="1">0.1443</td></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl2-note-0001"><p>Abbreviations: EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; SD, standard deviation; sig, signet&#x02010;ring cell carcinoma; tub, tubular adenocarcinoma; VM, vertical margin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270030-tbl-0003" content-type="TABLE"><label>TABLE 3</label><caption><p>Univariate and multivariate analyses of factors independently predictive of vertical margin (VM) &#x0003c;500 &#x000b5;m tumors.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Univariate analysis</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Multivariate analysis</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Characteristics</th><th align="left" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th><th align="left" rowspan="1" colspan="1">OR (95% CI)</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Colon location</td><td align="char" rowspan="1" colspan="1">1.58 (0.56&#x02013;5.15)</td><td align="char" rowspan="1" colspan="1">0.3999</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor size &#x02264;15 mm</td><td align="char" rowspan="1" colspan="1">2.52 (0.86&#x02013;9.23)</td><td align="char" rowspan="1" colspan="1">0.0931</td><td align="char" rowspan="1" colspan="1">3.20 (0.93&#x02013;13.76)</td><td align="char" rowspan="1" colspan="1">0.066</td></tr><tr><td align="left" rowspan="1" colspan="1">Superficial type</td><td align="char" rowspan="1" colspan="1">2.18 (0.91&#x02013;5.18)</td><td align="char" rowspan="1" colspan="1">0.0798</td><td align="char" rowspan="1" colspan="1">1.67 (0.61&#x02013;4.48)</td><td align="char" rowspan="1" colspan="1">0.3135</td></tr><tr><td align="left" rowspan="1" colspan="1">Type B lifting condition</td><td align="char" rowspan="1" colspan="1">9.00 (3.74&#x02013;23.01)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="char" rowspan="1" colspan="1">9.09 (3.65&#x02013;24.31)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Pathological T1b</td><td align="char" rowspan="1" colspan="1">1.08 (0.39&#x02013;3.29)</td><td align="char" rowspan="1" colspan="1">0.8818</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl3-note-0001"><p>Abbreviations: CI, confidence interval; OR, odds ratio; SM, submucosal; VM, vertical margin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec><sec id="deo270030-sec-0160"><title>Risk factors for short VMs according to tumor lifting conditions</title><p>The results revealed the tumor lifting condition was likely associated with the VM distance; therefore, we compared the clinicopathological characteristics of type A and type B tumors between the EMR and hybrid ESD groups to determine whether the VM distance was different (Tables&#x000a0;<xref rid="deo270030-tbl-0004" ref-type="table">4</xref> and&#x000a0;<xref rid="deo270030-tbl-0005" ref-type="table">5</xref>). Type A tumors exhibited no significant between&#x02010;group differences in clinicopathological characteristics or outcomes, including the VM distance (1000 [652&#x02013;2025] mm vs. 900 [500&#x02013;1800] mm, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.54) and proportion of VMs &#x02265;500 &#x000b5;m (80.0% [56/70] vs. 88.9% [16/18], <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.51). For type B tumors, the hybrid ESD group showed significantly longer VM distance (700 [500&#x02013;1925] mm vs. 0 [0&#x02013;400] mm, <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) and higher proportion of VMs &#x02265;500 &#x000b5;m (90.0% [9/10] vs. 8.7% [2/23], <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01) than did the EMR group. We also compared the clinical characteristics of tumors with type A and B lifting conditions to identify any pre&#x02010;injection factors that could predict type B lifting conditions (Table&#x000a0;<xref rid="deo270030-tbl-0006" ref-type="table">6</xref>). No significant between&#x02010;group differences were observed in the location, tumor size, and gross type.</p><table-wrap position="float" id="deo270030-tbl-0004" content-type="TABLE"><label>TABLE 4</label><caption><p>Clinicopathological characteristics and outcomes of tumors with the type A lifting condition in the endoscopic mucosal resection (EMR) and hybrid endoscopic submucosal dissection groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">EMR group</th><th align="left" rowspan="1" colspan="1">Hybrid ESD group</th><th align="char" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;70</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;18</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">70.1&#x000a0;&#x000b1;&#x000a0;8.5</td><td align="left" rowspan="1" colspan="1">66.8&#x000a0;&#x000b1;&#x000a0;11.1</td><td align="char" rowspan="1" colspan="1">0.1790</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">48 (68.6)</td><td align="char" rowspan="1" colspan="1">11 (61.1)</td><td align="char" rowspan="1" colspan="1">0.5814</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">22 (31.4)</td><td align="char" rowspan="1" colspan="1">7 (38.9)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Colon</td><td align="char" rowspan="1" colspan="1">62 (88.6)</td><td align="char" rowspan="1" colspan="1">13 (72.2)</td><td align="char" rowspan="1" colspan="1">0.1294</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">8 (11.4)</td><td align="char" rowspan="1" colspan="1">5 (27.8)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tumor size, mm, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">12.1&#x000a0;&#x000b1;&#x000a0;5.2</td><td align="left" rowspan="1" colspan="1">12.6&#x000a0;&#x000b1;&#x000a0;4.0</td><td align="char" rowspan="1" colspan="1">0.7221</td></tr><tr><td align="left" rowspan="1" colspan="1">Gross type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Protruded</td><td align="char" rowspan="1" colspan="1">59 (84.3)</td><td align="char" rowspan="1" colspan="1">12 (66.7)</td><td align="char" rowspan="1" colspan="1">0.1044</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Superficial</td><td align="char" rowspan="1" colspan="1">11 (15.7)</td><td align="char" rowspan="1" colspan="1">6 (33.3)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Main histology, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">70 (100)</td><td align="char" rowspan="1" colspan="1">17 (94.4)</td><td align="char" rowspan="1" colspan="1">0.2045</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">1 (5.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histology at the deepest invasive front, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">61 (87.1)</td><td align="char" rowspan="1" colspan="1">17 (94.4)</td><td align="char" rowspan="1" colspan="1">0.6800</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">9 (12.9)</td><td align="char" rowspan="1" colspan="1">1 (5.6)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic findings, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HGD</td><td align="char" rowspan="1" colspan="1">9 (12.9)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0.1407</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1a carcinoma</td><td align="char" rowspan="1" colspan="1">4 (5.7)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1b carcinoma</td><td align="char" rowspan="1" colspan="1">57 (81.4)</td><td align="char" rowspan="1" colspan="1">18 (100)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SM depth, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">2000 [1200&#x02013;4000]</td><td align="left" rowspan="1" colspan="1">2000 [1300&#x02013;2625]</td><td align="char" rowspan="1" colspan="1">0.8845</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion positive, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">22 (31.4)</td><td align="char" rowspan="1" colspan="1">8 (44.4)</td><td align="char" rowspan="1" colspan="1">0.4035</td></tr><tr><td align="left" rowspan="1" colspan="1">Budding grade 2/3, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">19 (27.1)</td><td align="char" rowspan="1" colspan="1">9 (50.0)</td><td align="char" rowspan="1" colspan="1">0.0885</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">70 (100)</td><td align="char" rowspan="1" colspan="1">18 (100)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">VM distance, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">1000 [652&#x02013;2025]</td><td align="left" rowspan="1" colspan="1">900 [500&#x02013;1800]</td><td align="char" rowspan="1" colspan="1">0.5379</td></tr><tr><td align="left" rowspan="1" colspan="1">VM &#x02265;500 &#x000b5;m, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">56 (80.0)</td><td align="char" rowspan="1" colspan="1">16 (88.9)</td><td align="char" rowspan="1" colspan="1">0.5076</td></tr><tr><td align="left" rowspan="1" colspan="1">VM1, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Rebleeding, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">2 (2.9)</td><td align="char" rowspan="1" colspan="1">1 (5.6)</td><td align="char" rowspan="1" colspan="1">0.5012</td></tr><tr><td align="left" rowspan="1" colspan="1">Perforation, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl4-note-0001"><p>Abbreviations: EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high&#x02010;grade dysplasia; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; SM, submucosal; SD, standard deviation; sig, signet&#x02010;ring cell carcinoma; tub, tubular adenocarcinoma; VM, vertical margin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270030-tbl-0005" content-type="TABLE"><label>TABLE 5</label><caption><p>Clinicopathological characteristics and outcomes of tumors with the type B lifting condition in the endoscopic mucosal resection and hybrid endoscopic submucosal dissection groups.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">EMR group</th><th align="left" rowspan="1" colspan="1">Hybrid ESD group</th><th align="left" rowspan="1" colspan="1"/></tr><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;23</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;10</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">69.8&#x000a0;&#x000b1;&#x000a0;10.5</td><td align="left" rowspan="1" colspan="1">71.1&#x000a0;&#x000b1;&#x000a0;10.4</td><td align="char" rowspan="1" colspan="1">0.7424</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Male</td><td align="char" rowspan="1" colspan="1">15 (65.2)</td><td align="char" rowspan="1" colspan="1">5 (50.0)</td><td align="char" rowspan="1" colspan="1">0.4611</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Female</td><td align="char" rowspan="1" colspan="1">8 (34.8)</td><td align="char" rowspan="1" colspan="1">5 (50.0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Colon</td><td align="char" rowspan="1" colspan="1">19 (82.6)</td><td align="char" rowspan="1" colspan="1">6 (60.0)</td><td align="char" rowspan="1" colspan="1">0.2054</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">4 (17.4)</td><td align="char" rowspan="1" colspan="1">4 (40.0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Tumor size, mm, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">10.7&#x000a0;&#x000b1;&#x000a0;4.5</td><td align="left" rowspan="1" colspan="1">15.2&#x000a0;&#x000b1;&#x000a0;3.9</td><td align="char" rowspan="1" colspan="1">0.0108</td></tr><tr><td align="left" rowspan="1" colspan="1">Gross type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Protruded</td><td align="char" rowspan="1" colspan="1">16 (69.6)</td><td align="char" rowspan="1" colspan="1">5 (50.0)</td><td align="char" rowspan="1" colspan="1">0.4334</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Superficial</td><td align="char" rowspan="1" colspan="1">7 (30.4)</td><td align="char" rowspan="1" colspan="1">5 (50.0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Main histology, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">21 (91.3)</td><td align="char" rowspan="1" colspan="1">10 (100)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">2 (8.7)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histology at the deepest invasive front, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">tub/pap</td><td align="char" rowspan="1" colspan="1">21 (91.3)</td><td align="char" rowspan="1" colspan="1">10 (100)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">por/sig/muc</td><td align="char" rowspan="1" colspan="1">2 (8.7)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Histologic findings, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">HGD</td><td align="char" rowspan="1" colspan="1">1 (4.4)</td><td align="char" rowspan="1" colspan="1">2 (20.0)</td><td align="char" rowspan="1" colspan="1">0.2990</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1a carcinoma</td><td align="char" rowspan="1" colspan="1">1 (4.4)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">T1b carcinoma</td><td align="char" rowspan="1" colspan="1">21 (91.2)</td><td align="char" rowspan="1" colspan="1">8 (80.0)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">SM depth, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">2200 [1300&#x02013;3000]</td><td align="left" rowspan="1" colspan="1">3000 [750&#x02013;4125]</td><td align="char" rowspan="1" colspan="1">0.3446</td></tr><tr><td align="left" rowspan="1" colspan="1">Vascular invasion positive, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">5 (21.7)</td><td align="char" rowspan="1" colspan="1">5 (50.0)</td><td align="char" rowspan="1" colspan="1">0.2148</td></tr><tr><td align="left" rowspan="1" colspan="1">Budding grade 2/3, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">3 (13.0)</td><td align="char" rowspan="1" colspan="1">4 (40.0)</td><td align="char" rowspan="1" colspan="1">0.1605</td></tr><tr><td align="left" rowspan="1" colspan="1">En bloc resection, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">21 (91.3)</td><td align="char" rowspan="1" colspan="1">10 (100)</td><td align="char" rowspan="1" colspan="1">1.0000</td></tr><tr><td align="left" rowspan="1" colspan="1">VM distance, &#x000b5;m, median [range]</td><td align="left" rowspan="1" colspan="1">0 [0&#x02013;400]</td><td align="left" rowspan="1" colspan="1">700 [500&#x02013;1925]</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">VM &#x02265;500 &#x000b5;m, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">2 (8.7)</td><td align="char" rowspan="1" colspan="1">9 (90.0)</td><td align="char" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Rebleeding, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td align="left" rowspan="1" colspan="1">Perforation, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">0 (0)</td><td align="char" rowspan="1" colspan="1">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl5-note-0001"><p>Abbreviations: EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; HGD, high&#x02010;grade dysplasia; muc, mucinous adenocarcinoma; pap, papillary adenocarcinoma; por, poorly differentiated adenocarcinoma; SD, standard deviation; sig, signet&#x02010;ring cell carcinoma; SM, submucosal; tub, tubular adenocarcinoma; VM, vertical margin.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap><table-wrap position="float" id="deo270030-tbl-0006" content-type="TABLE"><label>TABLE 6</label><caption><p>Clinical characteristics of tumors with type A and B lifting conditions.</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/><col align="char" char="." span="1"/><thead><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<p>Type A</p>
<p>
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;88</p>
</th><th align="left" rowspan="1" colspan="1">
<p>Type B</p>
<p>
<italic toggle="yes">n</italic>&#x000a0;=&#x000a0;33</p>
</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>&#x02010;value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Location, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Colon</td><td align="char" rowspan="1" colspan="1">75 (85.2)</td><td align="char" rowspan="1" colspan="1">25 (75.8)</td><td align="char" rowspan="1" colspan="1">0.2809</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Rectum</td><td align="char" rowspan="1" colspan="1">13 (14.8)</td><td align="char" rowspan="1" colspan="1">8 (24.2)</td><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Tumor size, mm, mean &#x000b1; SD</td><td align="left" rowspan="1" colspan="1">12.2&#x000a0;&#x000b1;&#x000a0;4.9</td><td align="left" rowspan="1" colspan="1">12.1&#x000a0;&#x000b1;&#x000a0;4.8</td><td align="char" rowspan="1" colspan="1">0.8826</td></tr><tr><td align="left" rowspan="1" colspan="1">Gross type, <italic toggle="yes">n</italic> (%)</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Protruded</td><td align="char" rowspan="1" colspan="1">71 (80.7)</td><td align="char" rowspan="1" colspan="1">21 (63.6)</td><td align="char" rowspan="1" colspan="1">0.0591</td></tr><tr><td style="padding-left:10%" align="left" rowspan="1" colspan="1">Superficial</td><td align="char" rowspan="1" colspan="1">17 (19.3)</td><td align="char" rowspan="1" colspan="1">12 (36.4)</td><td align="char" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="deo270030-tbl6-note-0001"><p>Abbreviation: SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd.</copyright-holder></permissions></table-wrap></sec></sec><sec id="deo270030-sec-0170"><title>DISCUSSION</title><p>Our study revealed indications for hybrid ESD for T1b CRCs &#x02264;20 mm to ensure adequate VMs according to tumor lifting conditions. We recommend performing hybrid ESD in tumors with type B lifting conditions.</p><p>Given the increasing number of patients requiring T1 CRC treatment,<xref rid="deo270030-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="deo270030-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="deo270030-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref> the proportion of ER procedures for T1 CRC has increased.<xref rid="deo270030-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> Because ER requires complete pathological resection for detailed pathological assessment, especially for T1 CRCs, a negative VM is an absolute requirement for curative resection.<xref rid="deo270030-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="deo270030-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="deo270030-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> Additionally, as ER for T1b CRCs with VMs &#x0003c;500 &#x000b5;m or VM1 tumors affects patient prognosis,<xref rid="deo270030-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> adequate VMs are important. We previously reported that submucosal fibrosis and poor differentiation at the deepest invasive portion are potential risk factors for VM1 in T1b CRCs,<xref rid="deo270030-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref> and that the EUS tumor&#x02010;free distance classification is a novel predictor of VM &#x02265;500 &#x000b5;m before ESD.<xref rid="deo270030-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref> However, we did not confirm any appropriate ER method that ensures adequate VMs.</p><p>Colorectal hybrid ESD planned in advance is reportedly useful. A prospective, randomized controlled study in Korea showed that planned hybrid ESD for colorectal neoplasia &#x02265;20 mm required a shorter time than did ESD (27.4 min vs. 40.6 min, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.005), with similar en bloc resection (94.1% vs. 100%, <italic toggle="yes">p</italic>&#x000a0;=&#x000a0;0.493) and perforation (8.8% vs. 6.5%, <italic toggle="yes">p</italic> &#x0003e; 0.999) rates.<xref rid="deo270030-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref> Okamoto et&#x000a0;al.<xref rid="deo270030-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref> revealed that planned colorectal hybrid ESD is safe for lesions measuring &#x02265;20&#x02013;&#x0003c;30 mm and results in complete en bloc resection. However, no consensus regarding hybrid ESD indications has been reached, and its usefulness for cT1b CRC and lesions &#x02264;20 mm remains unknown. In our study, we excluded CRCs treated using conventional ESD and simply compared EMR with hybrid ESD.</p><p>The non&#x02010;lifting sign,<xref rid="deo270030-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="deo270030-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> which involves a simple yes/no classification, is a straightforward tool to determine EMR indications. Generally, normal saline or 10% glycerin solution is injected into the submucosa to assess the non&#x02010;lifting sign.<xref rid="deo270030-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref> For lesions with positive non&#x02010;lifting signs, ESD (including hybrid ESD) or surgical resection can be performed because EMR is generally difficult and en bloc resection is desirable.<xref rid="deo270030-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref> Because cT1b CRCs resulting in VM1 with a negative non&#x02010;lifting sign after ER are not rare, a more detailed classification is necessary. Kato et&#x000a0;al.<xref rid="deo270030-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref> assessed the indications for and limitations of EMR for early CRC, focusing on tumor lifting after submucosal injection, and reported that these indications and limitations were easily assessed based on the tumor's lifting characteristics, which were significantly related to the invasion depth. We selected the tumor lifting condition after submucosal injection as a clinical tumor characteristic and classified it as type A, type B, or non&#x02010;lifting. Non&#x02010;lifting is characterized by a positive non&#x02010;lifting sign.</p><p>Based on our results, type B tumors were associated with VM1 and VM &#x0003c;500 &#x000b5;m. Type A tumors showed no significant between&#x02010;group differences, in contrast, for type B tumors, the VM distance was significantly longer and the proportion of VMs &#x02265;500 &#x000b5;m was significantly higher in the hybrid ESD group than in the EMR group. Therefore, we suggest the following strategy for cT1b CRCs &#x02264;20 mm to ensure adequate VMs. When the tumor lifting condition is type A, EMR can be performed; however, hybrid ESD can be considered for type A tumors that are difficult to resect with snaring alone because of their location, and for tumors that are difficult to classify as type A or B. When the tumor lifting condition is type B, hybrid ESD can be performed. Because the sample size for non&#x02010;lifting tumors was very small, we could not determine whether ESD (including hybrid ESD) or surgical resection is appropriate for non&#x02010;lifting tumors. Moreover, we could not identify any pre&#x02010;injection predictors of type B lifting conditions or specific differences in preoperative EUS findings between the lifting conditions.</p><p>Endoscopic images of EMR procedures for tumors with type B lifting conditions revealed that the snare tended to slip on the lifted mucosa during snaring and a smaller margin could be obtained, possibly resulting in a shorter VM distance. This can frequently occur in tumors with non&#x02010;lifting conditions. For lesions with massive submucosal invasion, dense fibrosis associated with invasive carcinoma prevents fluid infiltration through the submucosal connective tissue, thereby preventing bleb formation beneath the lesion, and the lesion is not elevated (non&#x02010;lifting sign).<xref rid="deo270030-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref> Therefore, the type B lifting condition is expected to be a prelude to the non&#x02010;lifting sign.</p><p>This study had some limitations. First, as a single&#x02010;center retrospective study, it had some inherent biases. Additionally, conventional ESD was excluded; these cases may show deeper invasion, and this could indicate a selection bias for cT1b CRCs. We performed preoperative EUS for all cT1b CRCs at our institution, and conventional and hybrid ESD was performed after confirming a certain distance between the deepest invasive tumor front and muscle layer. Second, indications for EMR and hybrid ESD were determined at the individual operator's discretion. Third, the sample size was relatively small, with few opportunities to select ER instead of surgical resection for cT1b CRCs. Fourth, the submucosal injection position is around the lesion in hybrid ESD and under the lesion in EMR; this slight difference may have partially affected decisions and tumor&#x02010;lifting conditions. However, this study targeted relatively small lesions (&#x0003c;20 mm); therefore, even during hybrid ESD, the first local injection is performed from the lesion's anal side to just below the lesion, and we evaluated the tumor lifting conditions during the first local injection. Finally, although the operators attempted to perform dissection just above the muscle layer before snaring during hybrid ESD, the treatment technique undeniably affected the results.</p><p>In conclusion, our novel classification of tumor lifting conditions can be a useful indicator for guiding decisions regarding the selection of EMR or hybrid ESD to ensure adequate VMs for cT1b CRCs &#x02264;20 mm.</p></sec><sec sec-type="COI-statement" id="deo270030-sec-0180"><title>CONFLICT OF INTEREST STATEMENT</title><p>None.</p></sec><sec id="deo270030-sec-0190"><title>ETHICS STATEMENT</title><p>This study was conducted in accordance with the Declaration of Helsinki. The use of patient data was approved by the Institutional Review Board of Hiroshima University (registration number: E&#x02010;241).</p></sec><sec id="deo270030-sec-0200"><title>PATIENT CONSENT STATEMENT</title><p>N/A.</p></sec></body><back><ref-list id="deo270030-bibl-0001"><title>REFERENCES</title><ref id="deo270030-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="deo270030-cit-0001">
<string-name>
<surname>Urabe</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Igarashi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Sugihara</surname>
<given-names>K</given-names>
</string-name>. <article-title>Impact of revisions of the JSCCR guidelines on the treatment of T1 colorectal carcinomas in Japan</article-title>. <source>Z Gastroenterol</source>
<year>2015</year>; <volume>53</volume>: <fpage>291</fpage>&#x02013;<lpage>301</lpage>.<pub-id pub-id-type="pmid">25860579</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0002"><label>2</label><mixed-citation publication-type="book" id="deo270030-cit-0002">
<string-name>
<surname>Hashiguchi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Muro</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<source>Japanese Society for Cancer of the Colon and Rectum Guidelines 2022 for the Treatment of Colorectal Cancer</source>, <edition>7th edn</edition>, <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanahara Publishing</publisher-name>, <year>2022</year>.</mixed-citation></ref><ref id="deo270030-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="deo270030-cit-0003">
<string-name>
<surname>Nakadoi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kanao</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2012</year>; <volume>27</volume>: <fpage>1057</fpage>&#x02013;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">22142484</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="deo270030-cit-0004">
<string-name>
<surname>Nakadoi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Condition of muscularis mucosae is a risk factor for lymph node metastasis in T1 colorectal carcinoma</article-title>. <source>Surg Endosc</source>
<year>2014</year>; <volume>28</volume>: <fpage>1269</fpage>&#x02013;<lpage>1276</lpage>.<pub-id pub-id-type="pmid">24281433</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="deo270030-cit-0005">
<string-name>
<surname>Miyachi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kudo</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Ichimasa</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Management of T1 colorectal cancers after endoscopic treatment based on the risk stratification of lymph node metastasis</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2016</year>; <volume>31</volume>: <fpage>1126</fpage>&#x02013;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">26641025</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="deo270030-cit-0006">
<string-name>
<surname>Yoshii</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nojima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Nosho</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Factors associated with risk for colorectal cancer recurrence after endoscopic resection of T1 tumors</article-title>. <source>Clin Gastroenterol Hepatol</source>
<year>2014</year>; <volume>12</volume>: <fpage>292</fpage>&#x02013;<lpage>302</lpage>.e3.<pub-id pub-id-type="pmid">23962552</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="deo270030-cit-0007">
<string-name>
<surname>Benson</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Venook</surname>
<given-names>AP</given-names>
</string-name>, <string-name>
<surname>Al&#x02010;Hawary</surname>
<given-names>MM</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Colon Cancer, version 2.2021, NCCN Clinical Practice Guidelines in Oncology</article-title>. <source>J Natl Compr Canc Netw</source>
<year>2021</year>; <volume>19</volume>: <fpage>329</fpage>&#x02013;<lpage>359</lpage>.<pub-id pub-id-type="pmid">33724754</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="deo270030-cit-0008">
<string-name>
<surname>Glynne&#x02010;Jones</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Wyrwicz</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Tiret</surname>
<given-names>E</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow&#x02010;up</article-title>. <source>Ann Oncol</source>
<year>2018</year>; <volume>29</volume>: <elocation-id>iv263</elocation-id>.<pub-id pub-id-type="pmid">29741565</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0009"><label>9</label><mixed-citation publication-type="book" id="deo270030-cit-0009">
<string-name>
<surname>Sugihara</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Ajioka</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ishiguro</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <source>Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma</source>, <edition>9th edn</edition>, <publisher-loc>Tokyo</publisher-loc>: <publisher-name>Kanahara Publishing</publisher-name>, <year>2018</year>.</mixed-citation></ref><ref id="deo270030-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="deo270030-cit-0010">
<string-name>
<surname>Nishimura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kamigaichi</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Vertical tumor margin of endoscopic resection for T1 colorectal carcinoma affects the prognosis of patients undergoing additional surgery</article-title>. <source>Surg Endosc</source>
<year>2022</year>; <volume>36</volume>: <fpage>5970</fpage>&#x02013;<lpage>5978</lpage>.<pub-id pub-id-type="pmid">35020058</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="deo270030-cit-0011">
<string-name>
<surname>Kudo</surname>
<given-names>S</given-names>
</string-name>. <article-title>Endoscopic mucosal resection of flat and depressed types of early colorectal cancer</article-title>. <source>Endoscopy</source>
<year>1993</year>; <volume>25</volume>: <fpage>455</fpage>&#x02013;<lpage>461</lpage>.<pub-id pub-id-type="pmid">8261988</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="deo270030-cit-0012">
<string-name>
<surname>Van Gossum</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Cozzoli</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Adler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Taton</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cremer</surname>
<given-names>M</given-names>
</string-name>. <article-title>Colonoscopic snare polypectomy: Analysis of 1485 resections comparing two types of current</article-title>. <source>Gastrointest Endosc</source>
<year>1992</year>; <volume>38</volume>: <fpage>472</fpage>&#x02013;<lpage>475</lpage>.<pub-id pub-id-type="pmid">1511824</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="deo270030-cit-0013">
<string-name>
<surname>Walsh</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Ackroyd</surname>
<given-names>FW</given-names>
</string-name>, <string-name>
<surname>Shellito</surname>
<given-names>PC</given-names>
</string-name>. <article-title>Endoscopic resection of large sessile colorectal polyps</article-title>. <source>Gastrointest Endosc</source>
<year>1992</year>; <volume>38</volume>: <fpage>303</fpage>&#x02013;<lpage>309</lpage>.<pub-id pub-id-type="pmid">1607080</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="deo270030-cit-0014">
<string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Tamai</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Standardization of endoscopic resection for colorectal tumors larger than 10 mm in diameter</article-title>. <source>Dig Endosc</source>
<year>2017</year>; <volume>29</volume> (Supplement <issue>2</issue>): <fpage>40</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">28425665</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="deo270030-cit-0015">
<string-name>
<surname>Uraoka</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ichihara</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Endoscopic management of colorectal tumors less than 10 mm in size: Current status and future perspectives in Japan from a questionnaire survey</article-title>. <source>Dig Endosc</source>
<year>2018</year>; <volume>30</volume> (Supplement <issue>1</issue>): <fpage>36</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">29658642</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="deo270030-cit-0016">
<string-name>
<surname>Ishiguro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Uno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Ishiguro</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Munakata</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>T</given-names>
</string-name>. <article-title>Correlation of lifting versus non&#x02010;lifting and microscopic depth of invasion in early colorectal cancer</article-title>. <source>Gastrointest Endosc</source>
<year>1999</year>; <volume>50</volume>: <fpage>329</fpage>&#x02013;<lpage>333</lpage>.<pub-id pub-id-type="pmid">10462651</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="deo270030-cit-0017">
<string-name>
<surname>Uno</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Munakata</surname>
<given-names>A</given-names>
</string-name>. <article-title>The non&#x02010;lifting sign of invasive colon cancer</article-title>. <source>Gastrointest Endosc</source>
<year>1994</year>; <volume>40</volume>: <fpage>485</fpage>&#x02013;<lpage>489</lpage>.<pub-id pub-id-type="pmid">7926542</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="deo270030-cit-0018">
<string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chayama</surname>
<given-names>K</given-names>
</string-name>. <article-title>Colorectal endoscopic submucosal dissection: Present status and future perspective, including its differentiation from endoscopic mucosal resection</article-title>. <source>J Gastroenterol</source>
<year>2008</year>; <volume>43</volume>: <fpage>641</fpage>&#x02013;<lpage>651</lpage>.<pub-id pub-id-type="pmid">18807125</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="deo270030-cit-0019">
<string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kanao</surname>
<given-names>H</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Current status in the occurrence of postoperative bleeding, perforation and residual/local recurrence during colonoscopic treatment in Japan</article-title>. <source>Dig Endosc</source>
<year>2010</year>; <volume>22</volume>: <fpage>376</fpage>&#x02013;<lpage>380</lpage>.<pub-id pub-id-type="pmid">21175503</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="deo270030-cit-0020">
<string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Terasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kanao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chayama</surname>
<given-names>K</given-names>
</string-name>. <article-title>Current status and future perspectives of endoscopic submucosal dissection for colorectal tumors</article-title>. <source>Dig Endosc</source>
<year>2012</year>; <volume>24</volume> Supplement (<issue>1</issue>): <fpage>73</fpage>&#x02013;<lpage>79</lpage>.<pub-id pub-id-type="pmid">22533757</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="deo270030-cit-0021">
<string-name>
<surname>Bae</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Optimized hybrid endoscopic submucosal dissection for colorectal tumors: A randomized controlled trial</article-title>. <source>Gastrointest Endosc</source>
<year>2016</year>; <volume>83</volume>: <fpage>584</fpage>&#x02013;<lpage>592</lpage>.<pub-id pub-id-type="pmid">26320696</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="deo270030-cit-0022">
<string-name>
<surname>Byeon</surname>
<given-names>JS</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>DH</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>KJ</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Endoscopic submucosal dissection with or without snaring for colorectal neoplasms</article-title>. <source>Gastrointest Endosc</source>
<year>2011</year>; <volume>74</volume>: <fpage>1075</fpage>&#x02013;<lpage>1083</lpage>.<pub-id pub-id-type="pmid">21663905</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="deo270030-cit-0023">
<string-name>
<surname>Toyonaga</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Man&#x02010;I</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Morita</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Azuma</surname>
<given-names>T</given-names>
</string-name>. <article-title>Endoscopic submucosal dissection (ESD) versus simplified/hybrid ESD</article-title>. <source>Gastrointest Endosc Clin N Am</source>
<year>2014</year>; <volume>24</volume>: <fpage>191</fpage>&#x02013;<lpage>199</lpage>.<pub-id pub-id-type="pmid">24679231</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="deo270030-cit-0024">
<string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kashida</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>JGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection</article-title>. <source>Dig Endosc</source>
<year>2015</year>; <volume>27</volume>: <fpage>417</fpage>&#x02013;<lpage>434</lpage>.<pub-id pub-id-type="pmid">25652022</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="deo270030-cit-0025">
<string-name>
<surname>Jung</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Byeon</surname>
<given-names>JS</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Factors predictive of complete excision of large colorectal neoplasia using hybrid endoscopic submucosal dissection: A KASID multicenter study</article-title>. <source>Dig Dis Sci</source>
<year>2018</year>; <volume>63</volume>: <fpage>2773</fpage>&#x02013;<lpage>2779</lpage>.<pub-id pub-id-type="pmid">29876776</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0026"><label>26</label><mixed-citation publication-type="book" id="deo270030-cit-0026">
<string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>. <part-title>Hybrid ESD</part-title>. In: <person-group person-group-type="editor">
<string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>
</person-group>, <person-group person-group-type="editor">
<string-name>
<surname>Saitoh</surname>
<given-names>Y</given-names>
</string-name>
</person-group>(eds). <source>Endoscopic Management of Colorectal T1 (SM) Carcinoma</source>, <publisher-loc>Singapore</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2022</year>; <fpage>87</fpage>&#x02013;<lpage>91</lpage>.</mixed-citation></ref><ref id="deo270030-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="deo270030-cit-0027">
<string-name>
<surname>Kanao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Clinical significance of type V(I) pit pattern subclassification in determining the depth of invasion of colorectal neoplasms</article-title>. <source>World J Gastroenterol</source>
<year>2008</year>; <volume>14</volume>: <fpage>211</fpage>&#x02013;<lpage>217</lpage>.<pub-id pub-id-type="pmid">18186557</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="deo270030-cit-0028">
<string-name>
<surname>Matsumoto</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Esaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hizawa</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Accuracy of radiographic assessment for the diagnosis of invasion depth in small invasive colorectal cancer</article-title>. <source>Br J Radiol</source>
<year>2003</year>; <volume>76</volume>: <fpage>611</fpage>&#x02013;<lpage>616</lpage>.<pub-id pub-id-type="pmid">14500275</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="deo270030-cit-0029">
<string-name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Marugame</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kamo</surname>
<given-names>K</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population&#x02010;based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project</article-title>. <source>Jpn J Clin Oncol</source>
<year>2012</year>; <volume>42</volume>: <fpage>139</fpage>&#x02013;<lpage>147</lpage>.<pub-id pub-id-type="pmid">22172347</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="deo270030-cit-0030">
<string-name>
<surname>Hori</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Matsuda</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Shibata</surname>
<given-names>A</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Cancer incidence and incidence rates in Japan in 2009: A study of 32 population&#x02010;based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project</article-title>. <source>Jpn J Clin Oncol</source>
<year>2015</year>; <volume>45</volume>: <fpage>884</fpage>&#x02013;<lpage>891</lpage>.<pub-id pub-id-type="pmid">26142437</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="deo270030-cit-0031">
<string-name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Colombet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Soerjomataram</surname>
<given-names>I</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018</article-title>. <source>Eur J Cancer</source>
<year>2018</year>; <volume>103</volume>: <fpage>356</fpage>&#x02013;<lpage>387</lpage>.<pub-id pub-id-type="pmid">30100160</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="deo270030-cit-0032">
<string-name>
<surname>Ozawa</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hayashi</surname>
<given-names>N</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Risk factors for vertical incomplete resection in endoscopic submucosal dissection as total excisional biopsy for submucosal invasive colorectal carcinoma</article-title>. <source>Int J Colorectal Dis</source>
<year>2013</year>; <volume>28</volume>: <fpage>1247</fpage>&#x02013;<lpage>1256</lpage>.<pub-id pub-id-type="pmid">23619616</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="deo270030-cit-0033">
<string-name>
<surname>Kamigaichi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanino</surname>
<given-names>F</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Novel endoscopic ultrasonography classification for assured vertical resection margin (&#x02265;500 &#x000b5;m) in colorectal endoscopic submucosal dissection</article-title>. <source>J Gastroenterol Hepatol</source>
<year>2022</year>; <volume>37</volume>: <fpage>2289</fpage>&#x02013;<lpage>2296</lpage>.<pub-id pub-id-type="pmid">36181255</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="deo270030-cit-0034">
<string-name>
<surname>Okamoto</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Oka</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tanaka</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Indications and outcomes of colorectal hybrid endoscopic submucosal dissection: A large multicenter 10&#x02010;year study</article-title>. <source>Surg Endosc</source>
<year>2022</year>; <volume>36</volume>: <fpage>1894</fpage>&#x02013;<lpage>1902</lpage>.<pub-id pub-id-type="pmid">33847798</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="deo270030-cit-0035">
<string-name>
<surname>Kobayashi</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sano</surname>
<given-names>Y</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al.</italic>
<article-title>Determining the treatment strategy for colorectal neoplastic lesions: Endoscopic assessment or the non&#x02010;lifting sign for diagnosing invasion depth?</article-title>
<source>Endoscopy</source>
<year>2007</year>; <volume>39</volume>: <fpage>701</fpage>&#x02013;<lpage>705</lpage>.<pub-id pub-id-type="pmid">17661244</pub-id>
</mixed-citation></ref><ref id="deo270030-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="deo270030-cit-0036">
<string-name>
<surname>Kato</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Haga</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Endo</surname>
<given-names>S</given-names>
</string-name>
<italic toggle="yes">et&#x000a0;al</italic>. <article-title>Lifting of lesions during endoscopic mucosal resection (EMR) of early colorectal cancer: Implications for the assessment of resectability</article-title>. <source>Endoscopy</source>
<year>2001</year>; <volume>33</volume>: <fpage>568</fpage>&#x02013;<lpage>573</lpage>.<pub-id pub-id-type="pmid">11473326</pub-id>
</mixed-citation></ref></ref-list></back></article>